Key data reveals for the small players

Evaluate Vantage has already previewed important upcoming first quarter data for big pharma and larger biotech groups. Now it is the turn of companies with a market cap of under $1bn.

Nordic Nanovector is finally set to deliver data with its much-delayed CD37 project Betalutin, while Proqr’s antisense project sepofarsen will set out its efficacy in a rare inherited eye disorder. Praxis, meanwhile, is hoping to jump on Sage/Biogen’s bandwagon with PRX-114, a Gaba A modulator in major depressive disorder.